Compare NRDY & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NRDY | XGN |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | United States | United States |
| Employees | N/A | 209 |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.4M | 138.9M |
| IPO Year | N/A | 2019 |
| Metric | NRDY | XGN |
|---|---|---|
| Price | $1.13 | $6.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $1.25 | ★ $13.67 |
| AVG Volume (30 Days) | ★ 1.8M | 258.8K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $177,867,000.00 | $63,599,000.00 |
| Revenue This Year | N/A | $21.76 |
| Revenue Next Year | $5.61 | $15.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.08 |
| 52 Week Low | $0.77 | $2.67 |
| 52 Week High | $2.02 | $12.23 |
| Indicator | NRDY | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.40 | 24.89 |
| Support Level | $1.09 | $5.93 |
| Resistance Level | $1.38 | $6.80 |
| Average True Range (ATR) | 0.12 | 0.35 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 6.25 | 9.47 |
Nerdy Inc is a curated direct-to-consumer platform for live online learning. Its proprietary platform leverages technology, including artificial intelligence ("AI"), to connect students, users, parents, guardians, and purchasers of all ages to tutors, instructors, subject matter experts, educators, and other professionals. The company provides learning experiences across numerous subjects and multiple formats, including one-on-one instruction, small group tutoring, large format classes, tutor chat, essay review, adaptive assessments, and self-study tools. The company generates revenue by selling services to learners and institutions for one-on-one instruction and small group tutoring.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.